NeuroSense Reports Positive Phase 2b PrimeC ALS Results
Cambridge, Massachusetts, March 16, 2026 NeuroSense Therapeutics Ltd. announced the publication of results from its PARADIGM Phase 2b clinical...
Neurodegenerative Disease
Advertisement
Parkinson’s IQ + You Empowers Nevada Patients
February 24, 2026 – New York, USA The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has announced that...
ANQUR Trial Shows STMN2 Restoration in ALS Patients
CAMBRIDGE, Mass., Feb. 23, 2026 — QurAlis announced interim clinical results from its Phase 1/2 ANQUR study demonstrating that...
Levacetylleucine Phase III Success in A-T Trial
AUSTIN, Texas, Feb. 12, 2026 — IntraBio announced positive topline results from its pivotal Phase III IB1001-303 clinical trial...
Vectory Doses First Patient in Phase 1/2 ALS Trial
Amsterdam, Netherlands | February 9 2026 — Vectory Therapeutics has announced that the first participant has been dosed in...
Advertisements
MIPLYFFA Real-World Data Strengthen NPC Treatment Impact
CELEBRATION, Fla., Feb. 4, 2026 —Zevra Therapeutics announced the presentation of positive new real-world data on MIPLYFFA® (arimoclomol) in...
Medicare Expands Access to Early Alzheimer’s Therapies
FAIRFAX, Va., January 22, 2026 — Re:Cognition Health announced that Medicare coverage is now available for FDA-approved amyloid-targeting therapies...
Sanofi Q3 2025 Results: Strong Growth and Key Approvals
PARIS – October 24, 2025 Sanofi reported a 7.0% sales increase at constant exchange rates (CER) for Q3 2025,...
Labcorp Expands Alzheimer’s Detection with FDA-Cleared Test
BURLINGTON, N.C. – October 23, 2025 Labcorp (NYSE: LH), a global leader in laboratory diagnostics, announced it will soon...
Alamar Biosciences Launches Blood-Based pTau217 Assay for Alzheimer’s Research
FREMONT, Calif., Oct. 10, 2025 /PRNewswire/ — Alamar Biosciences, a leader in precision proteomics, today announced the launch of...
Advertisement
